Kimberly-Clark Readies Asset Sales for EU Approval of Kenvue Deal

Kimberly-Clark is preparing asset concessions to secure EU antitrust approval for its $40 billion acquisition of Kenvue, following conditional clearances in Australia and South Africa. The deal combines hygiene brands with Kenvue's consumer health portfolio, including Tylenol and Aveeno.